Ovarian cancer patients could be helped by a test that identifies the specific type of tumour they have.
University researchers hope this improved diagnosis will help doctors to personalise treatment programmes so that patients receive the most effective drugs.
The Edinburgh team worked with scientists from Ireland to identify six subgroups of the disease, each of which had a different genetic signature.
To do this, they analysed tissue samples from more than 350 ovarian cancer patients and compared this information with the patients’ medical records.
The results show how genetic profiling of ovarian cancers might predict a person’s response to drug treatments.
Researchers say the development may be particularly helpful for women with an aggressive form of ovarian cancer, which is typically caught late by current diagnostic tests.
This type of aggressive - or ‘high grade’ - cancer can respond well to a recently-developed drug that targets the blood supply of the cancer cells.
The team hopes that by identifying the women with this type of cancer at the earliest opportunity, they could use the drug more effectively and help to improve survival rates.
The findings will be presented at the American Society of Clinical Oncology (ASCO) conference, being held in Chicago this week.
We have shown that by analysing the genes of ovarian cancers, we may be able to identify those patients who will respond well to new drug treatments. This could bring valuable improvements in survival rates for the disease and would help us to personalise a patient’s care to ensure the greatest possible success.
Dr Charlie Gourley
Senior Lecturer in Medical Oncology at the University
Ovarian cancer is the fifth most common cancer in women, with around 6,800 women being diagnosed every year in the UK.
Of these, nearly two-thirds will not live beyond five years of their diagnosis.
Chemotherapy and surgery can be effective treatments, but women could have a greater chance of surviving the disease if it is identified earlier on.
This article was published on Jun 9, 2011